Abstract
The article tells about the main stages of improving treatment regimens for acute lymphoblastic leukemia (ALL) in children, from monotherapy with prednisolone and 6-mercaptopurine to novel multicomponent risk-adapted chemotherapy protocols. The focus is on evaluating risk factors which varied with the expansion of knowledge about the molecular biological profile of ALL. Only the detailed analysis of the clinical and immunobiological characteristics of ALL allowed to develop novel, highly effective treatment schemes leading to recovery in over 80% of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
